The antitrust authority in Mexico fined five pharmaceutical companies for restricting the supply of medicines, fixing, manipulating and increasing the price of drugs in the Mexican market, for which they will have to pay an economic amount of 903 million 479,000 pesos, together.
The Plenary of the Federal Economic Competition Commission (Cofece) sanctioned Casa Marzam (Marzam), Casa Saba, Fármacos Nacionales (Fanasa), Nadro and Almacén de Drogas, as well as 21 individuals who participated on their behalf, for the carrying out absolute monopolistic practices in the drug distribution market, whose damage to Mexican consumers is estimated at 2,359 million pesos. In addition, the Association of Distributors of Pharmaceutical Products of the Mexican Republic (Diprofar) was also fined for assisting in the execution of said conduct.
According to file I0-001-2016 of the antitrust investigation, the collusion practice in the drug distribution market took place over a period of almost 10 years (from June 2006 to the end of December 2016 ), affecting the constitutional right to protect the health of the population and the income of families.
When carried out in one of the most relevant markets for the lives of Mexicans, Cofece, headed by Alejandra Palacios, argued that the damage to Mexican families was particularly for those with lower incomes, who spend approximately 24,000 million pesos in the purchase of medicines.
Through a statement, the Commission said that during the market control period, an agreement was presented between the Drug Store, Casa Saba, Fanasa, Marzam and Nadro, with the assistance of Diprofar, not to distribute drugs in the territory during the mandatory rest days provided for in the Federal Labor Law, as well as on Good Friday and Day of the Dead.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI